SCHEMBL5048718

SCHEMBL5048718

CCCCNC(=O)Oc1cc(-c2csc(-c3ccc(OC)cc3)n2)n(Cc2ccc(C(C)C)cc2)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4E P06730 2/20 0.41
MAPT P10636 5/20 0.39
TP53 P04637 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KLKB1 P03952 1/20 0.39
MGLL Q99685 1/20 0.39
THRB P10828 1/20 0.38
ATP4A P20648 2/20 0.38
ATP4B P51164 2/20 0.38
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CACNA1H O95180 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5039689 0.95 MAPT (0.43) EIF4EMAPTTP53SMN1; SMN2CYP3A4
SCHEMBL5044045 0.93 THRB (0.45) EIF4EMAPTTP53SMN1; SMN2CYP3A4
SCHEMBL5046059 0.91 EIF4E (0.46) EIF4EMAPTTP53CYP3A4CYP2C9
SCHEMBL5049186 0.91 NPC1 (0.41) EIF4EMAPTTP53SMN1; SMN2GAA
SCHEMBL5046039 0.89 CYP3A4 (0.41) MAPTTP53SMN1; SMN2GAACYP3A4
SCHEMBL5039553 0.88 KLKB1 (0.48) EIF4EMAPTTP53SMN1; SMN2KLKB1
SCHEMBL5046060 0.87 KLKB1 (0.43) EIF4EMAPTTP53SMN1; SMN2KLKB1
SCHEMBL5048696 0.82 CDC25A (0.43) MAPTTP53SMN1; SMN2KLKB1MGLL
SCHEMBL5046032 0.82 KLKB1 (0.53) EIF4EMAPTTP53SMN1; SMN2GAA
SCHEMBL5048635 0.81 MAPT (0.50) EIF4EMAPTTP53SMN1; SMN2KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP claimed